BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Cheetah, Hammerhead Shark, and 38 Other Animals in Danger of Extinction Receive New International Protections from U.N. - 2New India programme supports tribal families hosting tourists
- 3I decided to become a single mother by choice. I wasn't ready to stop dating.
- 45 Cell phones of the Year
- 55 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- Vote in favor of your Favored kind of pasta
- Nigeria’s return to Windsor castle signals new era in UK economic partnership
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- Hezbollah fires over 600 times at Israel, IDF troops over last 24 hours
- Sweet Taste? Candy Fulfills You
- How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- The Most Astonishing Arising Advances to Watch
